Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial.

Chest - 1 Dec 2012

Anderson William J, Short Philip M, Williamson Peter A, Lipworth Brian J

Abstract excerpt

BACKGROUND: International guidelines advocate a standard approach to asthma management for all, despite its heterogeneity. "Personalized" treatment of inflammatory asthma phenotypes confers superior benefits. We wished to evaluate dose response to inhaled corticosteroids (ICSs) in patients with asthma with an elevated fractional exhaled nitric oxide (Feno) phenotype using domiciliary measurements. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Inhalation
Share to Adrenal Cortex Hormones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Androstadienes

Share to Bronchodilator Agents

Share to Cross-Over Studies

Share to Double-Blind Method

Share to Exhalation

Share to Nitric Oxide

Source

Identifiers

PMID: 23364390
DOI: 10.1378/chest.12-1310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial.PMID 23364390Read ↗

MODERN APPROACHES TO FRACTIONAL EXHALED NITRIC OXIDE AS A USEFUL BIOMARKER FOR ALLERGIC ASTHMA PHENOTYPING AND MANAGEMENT.Semantic proximity Read ↗

FeNO as biomarker for asthma phenotyping and management.Semantic proximity Read ↗

Perspectives on exhaled nitric oxide.Semantic proximity Read ↗

Cutoff point for exhaled nitric oxide corresponding to 3% sputum eosinophils.Semantic proximity Read ↗

A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management.Semantic proximity Read ↗

Phenotypic predictors of response to oral glucocorticosteroids in severe asthma.Semantic proximity Read ↗

Biomarker-based asthma phenotypes of corticosteroid response.Semantic proximity Read ↗

Revisiting the role of exhaled nitric oxide in asthma.Semantic proximity Read ↗

Biologics in severe asthma: from precision phenotyping to clinical remission.Semantic proximity Read ↗

Measuring the corticosteroid responsiveness endophenotype in asthmatic patientsSemantic proximity Read ↗

Correlations between exhaled nitric oxide, rs28364072 polymorphism of FCER2 gene, asthma control, and inhaled corticosteroid responsiveness in children with asthma.Semantic proximity Read ↗

Recent advances in asthma biomarker research.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.